Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
NCT04910854Phase 2Unknown
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in Adenocarcinoma of the head and neck, sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
surufatinib
03
Conditions
Adenocarcinoma of the head and neck
Beyond the preview
Go deeper on NCT04910854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910854.